We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 71.07+0.5%Jul 12 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen11/14/2005 2:02:26 PM
   of 347
"Cytokine Storm" Paper Confirms GenoMed's Approach to Avian Flu

Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933

ST. LOUIS—November 14, 2005--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health, announced today that its approach to avian influenza was confirmed last week by a Hong Kong research group who found that the avian influenza virus induces a "cytokine storm" in human lung cells grown in tissue culture.

Dr. J.S.M. Peiris and colleagues published last week in Respiratory Research that avian influenza (H5N1) viruses isolated from dead patients cause lung cells to produce many more pro-inflammatory molecules, called "cytokines," than regular influenza A viral strains. This research confirms GenoMed's hypothesis that the host's immune response to the virus is what causes death, not the replication of the virus itself.

About GenoMed

GenoMed's broad-spectrum anti-viral approach is specifically mentioned in BioShield II, (see Section 2151 of Senate bill S. 975). GenoMed uses already existing, safe medication present in every drug store and hospital in the world. GenoMed is now charging a one-time license fee of US $10 to access its treatment approach, which is patent-pending globally. Please see for details.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext